<< Exhibitor
<< Press release
As a remarkable start with more than 1,100 exhibitors already registered, CACLP & CISCE 2024 are set to take center stage to present the latest achievements within the in-vitro diagnostic (IVD) industry.
The 21st China Association of Clinical Laboratory Practice Expo (CACLP) and the 4th China IVD Supply Chain Expo (CISCE) officially released that the upcoming event will be held from 16 - 18 March 2024 at Chongqing International Expo Center.
From 28 to 30 May 2023, the 20th China Association of Clinical Laboratory Practice Expo (CACLP) and the 3rd China IVD Supply Chain Expo (CISCE), recognized as the world’s leading in vitro diagnostics (IVD) exhibition, were successfully closed in Nanchang, China.
On May 28-29, The 10th China IVD Industry Development Conference (CIIDC) was successfully concluded at the Primus Hotel Nanchang International Expo City in Nanchang city. The conference attracted over 160,000 visits during the 2 days via livestreaming and onsite activities.
The 5th China IVD Distribution Enterprise Forum was held on May 26th, 2023 in Nanchang International Expo City, organized by CAIVD. The online live broadcast platform has reached 20,000 viewers.
On May 27, 2023, the 8th China Experimental Medicine Conference was held successfully at Primus Hotel Nanchang International Expo City.
The 3rd China Key Raw Material & Parts Forum (CKRMPF) was successfully wrapped up at Primus Hotel Nanchang International Expo City in May 2023.
Enlightening Lab Med - The 6th IVD Youth Entrepreneur Forum, organized by the China Association of In-Vitro Diagnostics (CAIVD), was held in Nanchang on May 26, 2023. The number of online viewers on the live streaming platform has reached 21,000.
The 3rd China Key Raw Material & Parts Forum (CKRMPF) is scheduled to be held at Primus Hotel Nanchang International Expo City on 28 May in 2023.
The 5th China IVD Distribution Enterprise Forum (CIDEF) is scheduled to be held at Primus Hotel Nanchang International Expo City on 26 May in 2023.
<< Industry news
Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.
PlumCare and Fabric Genomics said Thursday that they have partnered to integrate the Fabric AI platform with PlumCare’s FirstSteps newborn genome screening program in Greece.
Danish diagnostic firm Bioporto announced on Friday that its test for acute kidney injury in hospitalized children has received clearance from the US Food and Drug Administration.
Ad Astra Diagnostics (AAD), developer of rapid diagnostic systems, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its QScout™ rapid-result hematology system, which provides fast, point-of-care white blood cell counts (WBCs), neutrophil-to-lymphocyte ratio, and differentiates the number and percent of five types of mature WBCs as well as immature granulocytes.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.
Geneoscopy and Adiso Therapeutics announced on Tuesday a strategic collaboration that will involve the use of Geneoscopy's stool-based transcriptome platform to assess patient response to Adiso's experimental treatment for inflammatory bowel disease (IBD).
Danaher Corporation (NYSE:DHR) ("Danaher") announced today it has completed its acquisition of Abcam plc (NASDAQ:ABCM) ("Abcam").
Anhui Healthcare Security Administration in November issued a notice that a procurement involving 5 product categories and covering 25 provinces starts. The procurement will last 2 years.
First Light Diagnostics announced that the US Food and Drug Administration (FDA) has cleared its SensiTox® B. anthracis Toxin Test to be marketed in the U.S.
DiaCarta announced on Tuesday that its over-the-counter fecal occult blood test has received 510(k) clearance from the US Food and Drug Administration.
<< Video showcase
Gentian at CACLP 2023 Onsite
in.vent Diagnostics at CACLP 2023 Onsite
Charming Group at CACLP 2023 Onsite
Dialab at CACLP 2023 Onsite
JTC at CACLP 2023 Onsite
Certest at CACLP 2023 Onsite
Yashraj Biotechnology at CACLP 2023 Onsite
Magtivio at CACLP 2023 Onsite
The 8th China Experimental Medicine Conference (CEMC)
The 10th China IVD Industry Development Conference (CIIDC)
CACLP 2023 onsite - The Convergence of Laboratory Medicine and In Vitro Diagnostics
CACLP's new website is launching!
Autobio on Medlab Middle East 2023
EasyDiagnosis on Medlab Middle East 2023
BioPerfectus on Medlab Middle East 2023
YHLO on Medlab Middle East 2023
CACLP 2022 onsite - The World's Largest In Vitro Diagnostic products showcase
CACLP 2022 International Pavilion Welcome You!
CACLP 2022 International Pavilion Welcome You!
The 7th China Experimental Medicine Conference (CEMC)
<< Download centre
CACLP & CISCE 2023 Post-show Report
Over 1,100 Exhibitors Commit to Attend the 2024 China Association of Clinical Laboratory Practice Expo (CACLP) and China IVD Supply Chain Expo (CISCE)
CACLP & CISCE 2024 Flyer
Chongqing – The Next Station for China Association of Clinical Laboratory Practice Expo & China IVD Supply Chain Expo in 2024
The 20th CACLP & 3rd CISCE Closed with Record-breaking Numbers in Nanchang Last Week
CACLP & CISCE 2023 Floormap
Concerned about Travel Restrictions in China? Now Only a 48-hour Negative Nucleic Acid Report is Required
ANNIVERSARY EDITION OF CACLP AND CISCE TO EMPOWER FUTURE DEVELOPMENT OF THE IVD INDUSTRY
SUCCESSFUL RESULTS FOR CACLP 2022
ONLY ONE WEEK! 1,430 IVD EXHIBITORS ARE SET TO GATHER HERE
Copyright © 2023 GL events Ruihe (Shanghai) Exhibition Co., Ltd. All Rights Reserved. ( 沪ICP备12004745号-1 )
We deliver the latest IVD news straight to your inbox. Stay in touch with CACLP News.
sign-up for our newsletter today.
To ensure our newsletter hit your inbox, make sure to add @caclp.com to your safe senders list. And, as always, feel free to contact
us with any questions and thanks again for subscribing.
Go back
